Current Findings on the Spectrum of Neuronal Autoantibodies Associated with Psychotic Disorders
DOI:
https://doi.org/10.12974/2313-1047.2023.10.11Keywords:
Autoimmunity, Neural autoantibodies, Psychotic disorderAbstract
Background: Neural autoantibodies are observed in a subtype of psychotic disorders ranging from first-episode psychosis to schizophrenia. The clinical spectrum has so far been incompletely described, as new neuronal autoantibodies are emerging in the context of psychosis. This review is dedicated to describing the current spectrum of neural autoantibodies associated with psychotic disorders.
Methods: In our narrative review, we searched for neural autoantibodies addressed in the PubMed database in the last 15 years focusing on the last three years after publication of the international guidelines for autoimmune psychosis. We relied on small and large cohort studies and case series descriptions related to neural autoantibodies in psychotic disorders.
Results: Mainly neural autoantibodies against membrane surface structures such as N-Methyl-D-aspartate receptors (NMDAR) and against intracellular targets are present in psychotic disorders, but also in healthy controls. There is current suspicion that these neuronal autoantibodies (ie., NMDAR autoantibodies) play a potentially relevant role in the development of brain pathologies in psychotic disorders, especially when detected in cerebrospinal fluid. Autoantibodies against cell adhesion molecules and synaptic proteins such as neuronal cell adhesion molecule 1 (NCAM1) and antigen neurexin 1 alpha (NRXN1)-alpha occur in schizophrenia, but not in controls, suggesting that these are highly disease-specific antibodies. These lines of evidence are further supported by animal-model evidence showing a role of these autoantibodies in brain pathology and the development of schizophrenia-like symptoms.
Conclusions: In recent years, a new landscape of potentially relevant neural autoantibodies has emerged in a subtype of psychotic disorders. Their significance remains unclear. Large-scale investigations should particularly investigate what triggers the pathogenicity of these autoantibodies, as they probably do not cause the psychotic disorder per se, but might be involved as one factor in the immunopathophysiology. Psychotic disorders remain elusive, and differential diagnosis is required to determine the role neural autoantibodies play in the manifestation of psychoses.
References
Bai Y, Li W, Yan C, Hou Y, Wang Q. Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody. Front Immunol. 2023; 14: 1121705. https://doi.org/10.3389/fimmu.2023.1121705
Bejerot S, Eklund D, Hesser H, Hietala MA, Kariis T, Lange N, Lebedev A, Montgomery S, Nordenskjöld A, Petrovic P, Söderbergh A, Thunberg P, Wikström S, Humble MB; RCT-Rits study collaboration group. Study protocol for a randomized controlled trial with rituximab for psychotic disorder in adults (RCT-Rits). BMC Psychiatry. 2023; 23: 771. https://doi.org/10.1186/s12888-023-05250-5
Chandley M.J., Miller M.N., Kwasigroch C.N., Wilson T.D., Miller B.E. Increased antibodies for the alpha 7 subunit of the nicotinic receptor in schizophrenia. Schizophr. Res. 2009; 109: 98-101. https://doi.org/10.1016/j.schres.2009.01.023
Chia NH, McKeon A, Dalakas MC, Flanagan EP, Bower JH, Klassen BT, Dubey D, Zalewski NL, Duffy D, Pittock SJ, Zekeridou A. Stiff person spectrum disorder diagnosis, misdiagnosis, and suggested diagnostic criteria. Ann Clin Transl Neurol. 2023; 10: 1083-1094. https://doi.org/10.1002/acn3.51791
Daguano Gastaldi V, Bh Wilke J, Weidinger CA, Walter C, Barnkothe N, Teegen B, Luessi F, Stöcker W, Lühder F, Begemann M, Zipp F, Nave KA, Ehrenreich H. Factors predisposing to humoral autoimmunity against brain-antigens in health and disease: Analysis of 49 autoantibodies in over 7000 subjects. Brain Behav Immun. 2023; 108: 135-147. https://doi.org/10.1016/j.bbi.2022.10.016
Dalakas MC. Stiff-person Syndrome and GAD Antibody-spectrum Disorders: GABAergic Neuronal Excitability, Immunopathogenesis and Update on Antibody Therapies.Neurotherapeutics. 2022; 19: 832-847. https://doi.org/10.1007/s13311-022-01188-w
David C, McPherson PS, Mundigl O, de Camilli P. A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals.Proc Natl Acad Sci U S A. 1996; 93:331-5. https://doi.org/10.1073/pnas.93.1.331
Endres D, von Zedtwitz K, Matteit I, Bünger I, Foverskov-Rasmussen H, Runge K, Feige B, Schlump A, Maier S, Nickel K, Berger B, Schiele MA, Cunningham JL, Domschke K, Prüss H, Tebartz van Elst L. Spectrum of Novel Anti-Central Nervous System Autoantibodies in the Cerebrospinal Fluid of 119 Patients With Schizophreniform and Affective Disorders. Biol Psychiatry. 2022; 92: 261-274. https://doi.org/10.1016/j.biopsych.2022.02.010
Griffiths K, Mellado MR, Chung R, Lally J, McQueen G, Sendt KV, Gillespie A, Ibrahim M, Richter A, Shields A, Ponsford M, Jolles S, Hodsoll J, Pollak TA, Upthegrove R, Egerton A, MacCabe JH. Changes in immunoglobulin levels during clozapine treatment in schizophrenia. Brain Behav Immun. 2024; 115: 223-228. https://doi.org/10.1016/j.bbi.2023.10.001
Hansen N, Lipp M, Vogelgsang J, Vukovich R, Zindler T, Luedecke D, Gingele S, Malchow B, Frieling H, Kühn S, Denk J, Gallinat J, Skripuletz T, Moschny N, Fiehler J, Riedel C, Wiedemann K, Wattjes MP, Zerr I, Esselmann H, Bleich S, Wiltfang J, Neyazi A; CAP (Cerebrospinal Fluid Analysis in Psychiatry) Consortium. Autoantibody-associated psychiatric symptoms and syndromes in adults: A narrative review and proposed diagnostic approach.Brain Behav Immun Health. 2020; 9: 100154. https://doi.org/10.1016/j.bbih.2020.100154
Hansen N, Juhl AL, Grenzer IM, Teegen B, Wiltfang J, Fitzner D. Cerebrospinal fluid biomarkers in psychiatric autoimmune encephalitis: a retrospective cohort study.Front Psychiatry. 2023; 14: 1165153. https://doi.org/10.3389/fpsyt.2023.1165153
Hoffmann C, Zong S, Mané-Damas M, Stevens J, Malyavantham K, Küçükali Cİ, Tüzün E, De Hert M, van Beveren NJM, González-Vioque E, Arango C, Damoiseaux JGMC, Rutten BP, Molenaar PC, Losen M, Martinez-Martinez P. Schizophr Res. The search for an autoimmune origin of psychotic disorders: Prevalence of autoantibodies against hippocampus antigens, glutamic acid decarboxylase and nuclear antigens. 2021; 228: 462-471. https://doi.org/10.1016/j.schres.2020.12.038
Just D, Månberg A, Mitsios N, Stockmeier CA, Rajkowska G, Uhlén M, Mulder J, Feuk L, Cunningham JL, Nilsson P, Carlström EL. Exploring autoantibody signatures in brain tissue from patients with severe mental illness. Transl Psychiatry. 2020; 10: 401. https://doi.org/10.1038/s41398-020-01079-8
Keshavarz F, Soltani M, Mokhtarian K, Beshkar P, Majidi J, Azadegan-Dehkordi F, Anjomshoa M, Bagheri N. Autoantibodies against Central Nervous System Antigens and the Serum Levels of IL-32 in Patients with Schizophrenia. Neuroimmunomodulation. 2022; 29: 493-499. https://doi.org/10.1159/000526425
Lennox B, Xiong W, Waters P, Coles A, Jones PB, Yeo T, May JTM, Yeeles K, Anthony D, Probert F. The serum metabolomic profile of a distinct, inflammatory subtype of acute psychosis. Mol Psychiatry. 2022; 27: 4722-4730. https://doi.org/10.1038/s41380-022-01784-4
Melkersson K, Bensing S. Higher concentration in serum of insulin autoantibodies in patients with schizophrenia or related psychosis, compared to in control subjects. Neuro Endocrinol Lett. 2023; 44: 358-367.
Pan H, Oliveira B, Saher G, Dere E, Tapken D, Mitjans M, Seidel J, Wesolowski J, Wakhloo D, Klein-Schmidt C, Ronnenberg A, Schwabe K, Trippe R, Mätz-Rensing K, Berghoff S, Al-Krinawe Y, Martens H, Begemann M, Stöcker W, Kaup FJ, Mischke R, Boretius S, Nave KA, Krauss JK, Hollmann M, Lühder F, Ehrenreich H. Uncoupling the widespread occurrence of anti-NMDAR1 autoantibodies from neuropsychiatric disease in a novel autoimmune model. Mol Psychiatry. 2019; 24: 1489-1501. https://doi.org/10.1038/s41380-017-0011-3
Pechlivanidou M, Ninou E, Karagiorgou K, Tsantila A, Mantegazza R, Francesca A, Furlan R, Dudeck L, Steiner J, Tzartos J, Tzartos S. Autoimmunity to neuronal nicotinic acetylcholine receptors.Pharmacol Res. 2023; 192: 106790. https://doi.org/10.1016/j.phrs.2023.106790
Pollak TA, Kempton MJ, Iyegbe C, Vincent A, Irani SR, Coutinho E, Menassa DA, Jacobson L, de Haan L, Ruhrmann S, Sachs G, Riecher-Rössler A, Krebs MO, Amminger P, Glenthøj B, Barrantes-Vidal N, van Os J, Rutten BPF, Bressan RA, van der Gaag M, Yolken R, Hotopf M, Valmaggia L, Stone J, David AS; EUGEI High-Risk Study; McGuire P. Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis. Mol Psychiatry. 2021; 26: 2590-2604. https://doi.org/10.1038/s41380-020-00899-w
Reincke SM, von Wardenburg N, Homeyer MA, Kornau HC, Spagni G, Li LY, Kreye J, Sánchez-Sendín E, Blumenau S, Stappert D, Radbruch H, Hauser AE, Künkele A, Edes I, Schmitz D, Prüss H. Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells. Cell 2023;186: 5084-5097.e18. https://doi.org/10.1016/j.cell.2023.10.001
Ryan AE, Mowry BJ, Kesby JP, Scott JG, Greer JM. Is there a role for antibodies targeting muscarinic acetylcholine receptors in the pathogenesis of schizophrenia? Aust N Z J Psychiatry. 2019; 53: 1059-1069. https://doi.org/10.1177/0004867419864438
Shiwaku H, Katayama S, Gao M, Kondo K, Nakano Y, Motokawa Y, Toyoda S, Yoshida F, Hori H, Kubota T, Ishikawa K, Kunugi H, Ikegaya Y, Okazawa H, Takahashi H. Analyzing schizophrenia-related phenotypes in mice caused by autoantibodies against NRXN1α in schizophrenia. Brain Behav Immun. 2023; 111: 32-45. https://doi.org/10.1016/j.bbi.2023.03.028
Shiwaku H, Katayama S, Kondo K, Nakano Y, Tanaka H, Yoshioka Y, Fujita K, Tamaki H, Takebayashi H, Terasaki O, Nagase Y, Nagase T, Kubota T, Ishikawa K, Okazawa H, Takahashi H. Autoantibodies against NCAM1 from patients with schizophrenia cause schizophrenia-related behavior and changes in synapses in mice. Cell Rep Med. 2022; 3: 100597. https://doi.org/10.1016/j.xcrm.2022.100597
Tan CY, Goh KJ, Oh AW, Devaux J, Shahrizaila N. Autoantibody profile in a Malaysian cohort of chronic inflammatory demyelinating polyneuropathy. Neuromuscul Disord. 2022, 32: 255-262. https://doi.org/10.1016/j.nmd.2022.01.006
Timäus C, von Gottberg P, Hirschel S, Lange C, Wiltfang J, Hansen N. KCNA2 Autoimmunity in Progressive Cognitive Impairment: Case Series and Literature Review. Brain Sci. 2021; 11:89. https://doi.org/10.3390/brainsci11010089
von Zedtwitz K, Matteit I, Michel M, Feige B, Runge K, Denzel D, Schlump A, Nickel K, Schiele MA, Berger B, Prüss H, Urbach H, Domschke K, Tebartz van Elst L, Endres D. Anti-MOG autoantibody-associated schizophreniform psychosis. Acta Neuropsychiatr. 2022; 34: 47-54. https://doi.org/10.1017/neu.2021.29
Warren N, Freier K, Siskind D, O'Gorman C, Blum S, Gillis D, Scott JG.Aust N Z J Psychiatry. Anti-glutamic acid decarboxylase antibody screening in first-episode psychosis. 2023; 57: 603-612. https://doi.org/10.1177/00048674221089560
Wcisło S, Bojkowska-Otrębska K, Łabuz-Roszak B. Psychiatric disorders in autoimmune encephalitis- literature review. Pol Merkur Lekarski. 2023; 51: 563-568. https://doi.org/10.36740/Merkur202305117
Zandian A, Wingård L, Nilsson H, Sjöstedt E, Johansson DX, Just D, Hellström C, Uhlén M, Schwenk JM, Häggmark-Månberg A, Norbeck O, Owe-Larsson B, Nilsson P, Persson MAA. Untargeted screening for novel autoantibodies with prognostic value in first-episode psychosis. Transl Psychiatry. 2017; 7: e1177. https://doi.org/10.1038/tp.2017.160
Zhou D, Xie C, Li X, Song N, Kou Z, Zhang T, Yuan TF. Rare presence of autoantibodies targeting to NMDA and GABAA receptors in schizophrenia patients. Schizophr Res. 2022; 249: 93-97. https://doi.org/10.1016/j.schres.2021.12.002
